Skip to content
All Sections
Subscribe Now
62°F
Sunday, September 29th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
62°F
Sunday, September 29th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Latest Trump news
Man hit, killed by fire engine
Affordable senior housing opens
Westbrook Academy reopens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Repare Therapeutics Inc.
< Previous
1
2
Next >
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
September 23, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
September 13, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
August 28, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
August 27, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
June 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
June 10, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
June 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
May 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
May 07, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
April 30, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
April 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
February 15, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Regain Global Rights to Camonsertib
February 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
January 25, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
January 08, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
January 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 29, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
November 15, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
November 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
October 13, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 03, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close